Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 4Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Small Cell Lung Cancer Limited Stage 1Radiotherapy 1Liver Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Tumours 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1

Interventions

Sorafenib 12Radiosurgery 5Gemcitabine 5Capecitabine 5Bevacizumab 5Radiotherapy 4Fluorouracil 4Doxorubicin 4Sunitinib 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3seocalcitol 2regorafenib 2phosphomannopentaose sulfate 2atezolizumab 2Thiotepa 2Radiofrequency Ablation 2Melphalan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Filgrastim 2Dexamethasone 2Cisplatin 2Chemoembolization, Therapeutic 2Carboplatin 2Busulfan 2Brachytherapy 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Liver Neoplasms × toripalimab × Clear all
NCT05427396 2025-12-03

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Terminated
31 enrolled
GastrointestinalGynecologic

Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡